Original Research
Published on 20 Oct 2025
Polysialic acid restrains inflammatory monocyte maturation
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1656087
- 137 views
Type at least 3 characters
1,446 articles
Original Research
Published on 20 Oct 2025
Neutrophils from Alzheimer’s disease mice fail to phagocytose debris and show altered release of immune modulators with age
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1672768
- 1,038 views
Original Research
Published on 20 Oct 2025
Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1694021
- 296 views
Original Research
Accepted on 17 Oct 2025
Antibodies to Myelin Oligodendrocyte Glycoprotein in Optic perineuritis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1657600
- 109 views
Original Research
Accepted on 15 Oct 2025
Sex differences in abnormal gluten response and predictors of gluten sensitivity in patients with schizophrenia
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1696763
- 118 views
Review
Published on 15 Oct 2025
The link between gut microbiota and multiple sclerosis from the perspective of barrier function
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1652796
- 1,494 views
Review
Accepted on 14 Oct 2025
The mechanisms of specialized pro-resolving mediators in pain relief: Neuro-immune and neuroglial regulations
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1634724
- 122 views
Original Research
Accepted on 13 Oct 2025
The ATP-mediated cytokine release by macrophages is down-modulated by unconventional α9* nicotinic acetylcholine receptors
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1661114
Original Research
Accepted on 13 Oct 2025
Intestinal Mucosal Alterations Parallel Central Demyelination and Remyelination: Insights into the Gut-Brain Axis in the Cuprizone Model of Multiple Sclerosis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1682183
- 215 views
Original Research
Published on 13 Oct 2025
Colonization by Akkermansia muciniphila modulates central nervous system autoimmunity in an ecological context-dependent manner
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1655428
- 1,046 views
Original Research
Accepted on 08 Oct 2025
The diagnostic and prognostic value of CXCL13, CXCL10, and CXCL8 in patients with neurosyphilis
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1654251
- 261 views
Systematic Review
Published on 08 Oct 2025
Research on Parkinson’s disease immunotherapy: a bibliometric analysis via multiple databases
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1659848
- 2,218 views
Perspective
Published on 07 Oct 2025
Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1681724
- 1,061 views
Review
Published on 07 Oct 2025
Glycolytic reprogramming during microglial polarization in neurological diseases
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1648887
- 1,791 views
Study Protocol
Accepted on 06 Oct 2025
The efficacy, safety, and PK/PDpharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1604786
- 313 views
Original Research
Accepted on 06 Oct 2025
Global, regional, and national trends and burden of multiple sclerosis in adolescents and young adults: A data analysis from 1990 to 2021 and projections to 2040
in Multiple Sclerosis and Neuroimmunology
Frontiers in Immunology
doi 10.3389/fimmu.2025.1685316
- 179 views